Results for "consumer data right"
451-460 of 549 results for 'consumer data right'
New ASIC guidance on how superannuation and managed funds can avoid 'greenwashing'
Greenwashing in the promotion of managed investment and superannuation funds is one of ASIC's current corporate governance priorities as it continues to 'monitor the market … looking for misleading claims about ESG and sustainability'. ...
ASIC ramps up greenwashing-related regulatory interventions, targeting managed funds and ASX listed entities
ASIC's latest report, ASIC's recent greenwashing interventions (the Report), outlines its recent surveillance activities and regulatory interventions to tackle misleading marketing and greenwashing. ...
Proposed RG 97 stamp duty and PHD private credit changes on the horizon
ASIC has announced proposed: limited changes to the way stamp duty will be disclosed under Regulatory Guide 97 Disclosing fees and costs in PDSs and periodic statements (RG 97), which are the rules f ...
Major proposed changes to FIRB regime
On 5 June 2020 the Federal Treasurer announced major proposed changes to Australia's FIRB regime to address national security risks and ensure greater compliance with FIRB approval conditions. ...
World first: Australia says ‘yes’ to AI inventors
The decision in Thaler v Commissioner of Patents [2021] FCA 879 is the first judicial determination in the world in favour of AI systems being named as inventors of a patent. The availability of patent protection for AI-generated inventions is a vexed and controversial issue. ...
Nucleus – corporate law developments: major FIRB law changes; ASIC extends relief for financial reporting and AGM requirements; and other corporate law developments
Major foreign investment law changes; ASIC extends relief for financial reporting and AGM requirements and issues guidance on design and distribution laws; ASX issues guidance to address 'earning surprises'; ACCC releases first digital platform inquiry interim report; and WA Supreme Court hands down decision with implications for legal professional privilege in internal emails. ...
Patent term extensions under siege: a new era of challenges for pharmaceutical patentees
A recent Federal Court decision has struck down a patent term extension granted to Novartis for its blockbuster heart failure drug Entresto. The decision in Novartis AG v Pharmacor Pty Limited follows a recent trend of successful challenges by generic pharmaceutical companies. ...
Interlocutory injunction refused based on 'doubtful' patent term extension
In the fight against patent infringement, challenging the validity of patent term extensions (PTEs) is increasingly becoming the weapon of choice for generic pharmaceutical companies. Since around the mid-2000s, patentees in pharmaceutical patent cases have typically been successful in bids for interlocutory injunctions, aiming to prevent the launch of generic products in Australia. The recent Biogen decision by the Federal Court is the latest in a trend of refusing interlocutory injunctions, and a clear indication the tide is turning. ...
Regulatory scrutiny of private capital increases
Private capital is becoming a growing focus of regulators, both in Australia and internationally, given the ever-increasing flow of capital to the sector in recent years. ...
Nucleus – corporate law developments
Welcome to our monthly snapshot of regulatory updates and other developments in corporate law. We know you are busy, so our focus is on capturing key issues. ...